| Jennifer Johnson, CNM | |
|
1493 Cambridge St, Cambridge, MA 02139 | |
| (617) 665-1000 | |
| Not Available |
| Full Name | Jennifer Johnson |
|---|---|
| Gender | Female |
| Speciality | Advanced Practice Midwife |
| Location | 1493 Cambridge St, Cambridge, Massachusetts |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932649555 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | F001772-1 (New York) | Secondary |
| 367A00000X | Advanced Practice Midwife | RN2324236 (Massachusetts) | Primary |
| Entity Name | Abington Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821042508 PECOS PAC ID: 3274437736 Enrollment ID: O20040115000001 |
News Archive
Biogen Idec announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a negative opinion recommending against approval of FAMPYRA to improve walking ability in adult patients with multiple sclerosis (MS) in the European Union. Biogen Idec intends to appeal this opinion and request a re-examination of the decision by the CHMP.
Less nutritious dietary choices made by South Asians living in developed countries like the U.S. are a key contributor to the group's rising rate of Type 2 diabetes, UT Southwestern researchers report.
The results of two studies presented today at the Annual European Congress of Rheumatology (EULAR) 2017 press conference highlight the use of two new tools, which can potentially play a pivotal role in the early diagnosis of Systemic Sclerosis.
Which antiplatelet medication is best after a coronary stent? The Tailored Antiplatelet Therapy to Lessen Outcomes After Percutaneous Coronary Intervention (TAILOR-PCI) Study examines whether prescribing heart medication based on a patient's CYP2C19 genotype will help prevent heart attack, stroke, unstable angina, and cardiovascular death in patients who undergo percutaneous coronary intervention (PCI), commonly called angioplasty.
› Verified 9 days ago
| Entity Name | Abington Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1316189855 PECOS PAC ID: 3274437736 Enrollment ID: O20091218000204 |
News Archive
Biogen Idec announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a negative opinion recommending against approval of FAMPYRA to improve walking ability in adult patients with multiple sclerosis (MS) in the European Union. Biogen Idec intends to appeal this opinion and request a re-examination of the decision by the CHMP.
Less nutritious dietary choices made by South Asians living in developed countries like the U.S. are a key contributor to the group's rising rate of Type 2 diabetes, UT Southwestern researchers report.
The results of two studies presented today at the Annual European Congress of Rheumatology (EULAR) 2017 press conference highlight the use of two new tools, which can potentially play a pivotal role in the early diagnosis of Systemic Sclerosis.
Which antiplatelet medication is best after a coronary stent? The Tailored Antiplatelet Therapy to Lessen Outcomes After Percutaneous Coronary Intervention (TAILOR-PCI) Study examines whether prescribing heart medication based on a patient's CYP2C19 genotype will help prevent heart attack, stroke, unstable angina, and cardiovascular death in patients who undergo percutaneous coronary intervention (PCI), commonly called angioplasty.
› Verified 9 days ago
| Entity Name | Abington Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366835571 PECOS PAC ID: 3274437736 Enrollment ID: O20150624002498 |
News Archive
Biogen Idec announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a negative opinion recommending against approval of FAMPYRA to improve walking ability in adult patients with multiple sclerosis (MS) in the European Union. Biogen Idec intends to appeal this opinion and request a re-examination of the decision by the CHMP.
Less nutritious dietary choices made by South Asians living in developed countries like the U.S. are a key contributor to the group's rising rate of Type 2 diabetes, UT Southwestern researchers report.
The results of two studies presented today at the Annual European Congress of Rheumatology (EULAR) 2017 press conference highlight the use of two new tools, which can potentially play a pivotal role in the early diagnosis of Systemic Sclerosis.
Which antiplatelet medication is best after a coronary stent? The Tailored Antiplatelet Therapy to Lessen Outcomes After Percutaneous Coronary Intervention (TAILOR-PCI) Study examines whether prescribing heart medication based on a patient's CYP2C19 genotype will help prevent heart attack, stroke, unstable angina, and cardiovascular death in patients who undergo percutaneous coronary intervention (PCI), commonly called angioplasty.
› Verified 9 days ago
| Entity Name | Abington Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1548825243 PECOS PAC ID: 3274437736 Enrollment ID: O20190723002404 |
News Archive
Biogen Idec announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a negative opinion recommending against approval of FAMPYRA to improve walking ability in adult patients with multiple sclerosis (MS) in the European Union. Biogen Idec intends to appeal this opinion and request a re-examination of the decision by the CHMP.
Less nutritious dietary choices made by South Asians living in developed countries like the U.S. are a key contributor to the group's rising rate of Type 2 diabetes, UT Southwestern researchers report.
The results of two studies presented today at the Annual European Congress of Rheumatology (EULAR) 2017 press conference highlight the use of two new tools, which can potentially play a pivotal role in the early diagnosis of Systemic Sclerosis.
Which antiplatelet medication is best after a coronary stent? The Tailored Antiplatelet Therapy to Lessen Outcomes After Percutaneous Coronary Intervention (TAILOR-PCI) Study examines whether prescribing heart medication based on a patient's CYP2C19 genotype will help prevent heart attack, stroke, unstable angina, and cardiovascular death in patients who undergo percutaneous coronary intervention (PCI), commonly called angioplasty.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jennifer Johnson, CNM 1493 Cambridge St, Cambridge, MA 02139-1047 Ph: (617) 665-1000 | Jennifer Johnson, CNM 1493 Cambridge St, Cambridge, MA 02139 Ph: (617) 665-1000 |
News Archive
Biogen Idec announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a negative opinion recommending against approval of FAMPYRA to improve walking ability in adult patients with multiple sclerosis (MS) in the European Union. Biogen Idec intends to appeal this opinion and request a re-examination of the decision by the CHMP.
Less nutritious dietary choices made by South Asians living in developed countries like the U.S. are a key contributor to the group's rising rate of Type 2 diabetes, UT Southwestern researchers report.
The results of two studies presented today at the Annual European Congress of Rheumatology (EULAR) 2017 press conference highlight the use of two new tools, which can potentially play a pivotal role in the early diagnosis of Systemic Sclerosis.
Which antiplatelet medication is best after a coronary stent? The Tailored Antiplatelet Therapy to Lessen Outcomes After Percutaneous Coronary Intervention (TAILOR-PCI) Study examines whether prescribing heart medication based on a patient's CYP2C19 genotype will help prevent heart attack, stroke, unstable angina, and cardiovascular death in patients who undergo percutaneous coronary intervention (PCI), commonly called angioplasty.
› Verified 9 days ago
Gisela Jung-seifert, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 1493 Cambridge St, Cambridge, MA 02139 Phone: 617-665-2229 | |
Kam-ling L Ma, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 1493 Cambridge St, Cambridge, MA 02139 Phone: 617-665-1309 | |
Ms. Juhi J Khamar, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 1493 Cambridge St, Cambridge, MA 02139 Phone: 617-665-1616 Fax: 617-665-1976 | |
Kathellen T Reist, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 1493 Cambridge St, Cambridge, MA 02139 Phone: 617-665-2229 | |
Mrs. Cassandra Kugler, CNM, WHNP-BC Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 1493 Cambridge St, Cambridge, MA 02139 Phone: 314-960-4449 | |
Margi L Coggins, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 1493 Cambridge St, Cambridge, MA 02139 Phone: 617-665-2229 | |
Ms. Vera Sichko-seltzer, MS, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 330 Mount Auburn St, Cambridge, MA 02138 Phone: 617-499-5130 Fax: 617-499-5103 |